Mnta: if the downside is only 22% and MNTA has all it's growth ahead of itself, that's not a huge risk to take for a developmental stage bio moving into an operational bio. I think Deutsche Bank predicted that MNTA and Teva were going to get approval possibly simultaneously. When that didn't happen, I think the odds should have slightly changed. If MNTA is still the sole generic in 6 months, analysts will be more likely to go out on a limb and raise the odds of the possibility of a sole generic.
Market Data 
Markets 
AI
